Phenotypic plasticity of ER+ breast cancer in the bone microenvironment

ER+ breast cancer exhibits a strong bone-tropism in metastasis. How the bone microenvironment impacts the ER signaling and endocrine therapies remains poorly understood. Here, we discover that the osteogenic niche transiently reduces ER expression and activities specifically in bone micrometastases (BMMs), leading to endocrine resistance. This is mediated by gap junctions and paracrine FGF/PDGF signaling, which together generate a stable “memory”: cancer cells extracted from bone remain resistant to endocrine therapies for several generations. Using single cell-derived populations (SCPs), we demonstrated that this process is independent of clonal selection, and represents an EZH2-mediated epigenomic reprogramming. EZH2 drives ER+ BMMs toward a basal and stem-like state. EZH2 inhibition reverses endocrine resistance. Our data demonstrates how epigenomic adaptation to the bone microenvironment drives phenotypic plasticity of metastatic seeds and alters their therapeutic responses together with clonal selection, and provides insights into the clinical enigma of ER+ metastatic recurrences despite endocrine therapies.

[1]  X. Zhang,et al.  The bone microenvironment invigorates metastatic seeds for further dissemination , 2020, Cell.

[2]  Yibin Kang,et al.  Bone Vascular Niche E-selectin Induces Mesenchymal-Epithelial Transition and Wnt Activation in Cancer Cells to Promote Bone Metastasis , 2019, Nature Cell Biology.

[3]  Gan‐Lin Zhang,et al.  Orthotopic Injection of Breast Cancer Cells into the Mice Mammary Fat Pad. , 2019, Journal of visualized experiments : JoVE.

[4]  Piyush B. Gupta,et al.  Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance. , 2019, Cell stem cell.

[5]  Stephen T. C. Wong,et al.  The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability. , 2018, Cancer cell.

[6]  G. Wahl,et al.  Epigenetic and Transcriptomic Profiling of Mammary Gland Development and Tumor Models Disclose Regulators of Cell State Plasticity. , 2018, Cancer cell.

[7]  Min Huang,et al.  Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors , 2018, Cell.

[8]  George M. Church,et al.  Developmental barcoding of whole mouse via homing CRISPR , 2018, Science.

[9]  P. V. van Diest,et al.  Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis , 2018, Journal of the National Cancer Institute.

[10]  W. El-Deiry,et al.  Faculty of 1000 evaluation for Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. , 2018 .

[11]  Daniel J. Blankenberg,et al.  The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update , 2018, Nucleic Acids Res..

[12]  T. Owa,et al.  Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. , 2018, The Lancet. Oncology.

[13]  Joshua M. Stuart,et al.  Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. , 2018, Cell.

[14]  Gustav Stålhammar,et al.  Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes , 2018, The Journal of clinical investigation.

[15]  L. Saal,et al.  Microenvironmental control of breast cancer subtype elicited by paracrine platelet derived growth factor-CC signaling , 2018, Nature Medicine.

[16]  Yibin Kang,et al.  Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy. , 2017, Cancer cell.

[17]  Rohit Bhargava,et al.  Exome-capture RNA-sequencing of decade-old breast cancers and matched decalcified bone metastases identifies clinically actionable targets , 2017, bioRxiv.

[18]  Stephen T. C. Wong,et al.  Bone-in-culture array as a platform to model early-stage bone metastases and discover anti-metastasis therapies , 2017, Nature Communications.

[19]  Lajos Pusztai,et al.  Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations , 2017, Nature Communications.

[20]  R. Weinberg,et al.  Emerging Biological Principles of Metastasis , 2017, Cell.

[21]  A. Welm,et al.  RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis , 2017, Science Translational Medicine.

[22]  X. Zhang,et al.  Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis. , 2016, Journal of visualized experiments : JoVE.

[23]  D. Edwards,et al.  Erratum: Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation , 2016, Nature Cell Biology.

[24]  D. Mankoff,et al.  Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer , 2016, Clinical Cancer Research.

[25]  George M. Church,et al.  Rapidly evolving homing CRISPR barcodes , 2016, Nature Methods.

[26]  D. Edwards,et al.  Oncogenic mTOR signaling recruits myeloid-derived suppressor cells to promote tumor initiation , 2016, Nature Cell Biology.

[27]  Dennis Wang,et al.  Combenefit: an interactive platform for the analysis and visualization of drug combinations , 2016, Bioinform..

[28]  C. Roberts,et al.  Targeting EZH2 in cancer , 2016, Nature Medicine.

[29]  U. Jeschke,et al.  Estrogen Receptor and HER2 Status on Disseminated Tumor Cells and Primary Tumor in Patients with Early Breast Cancer , 2015, Translational oncology.

[30]  D. Edwards,et al.  Mammary Stem Cells and Tumor-Initiating Cells Are More Resistant to Apoptosis and Exhibit Increased DNA Repair Activity in Response to DNA Damage , 2015, Stem cell reports.

[31]  Tim J. Wigle,et al.  EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity , 2015, ACS medicinal chemistry letters.

[32]  Stephen T. C. Wong,et al.  The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. , 2015, Cancer cell.

[33]  Michael Q. Zhang,et al.  Integrative analysis of 111 reference human epigenomes , 2015, Nature.

[34]  G. Wahl,et al.  Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy , 2015, Breast Cancer Research and Treatment.

[35]  Howard Y. Chang,et al.  ATAC‐seq: A Method for Assaying Chromatin Accessibility Genome‐Wide , 2015, Current protocols in molecular biology.

[36]  J. Gustafsson,et al.  ERβ decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway , 2014, Oncogene.

[37]  Fidel Ramírez,et al.  deepTools: a flexible platform for exploring deep-sequencing data , 2014, Nucleic Acids Res..

[38]  Paul Greengard,et al.  Cell type–specific mRNA purification by translating ribosome affinity purification (TRAP) , 2014, Nature Protocols.

[39]  Xia Li,et al.  EZH2 expands breast stem cells through activation of NOTCH1 signaling , 2014, Proceedings of the National Academy of Sciences.

[40]  R. Schiff,et al.  Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer , 2013, Clinical Cancer Research.

[41]  David E Larson,et al.  Using VarScan 2 for Germline Variant Calling and Somatic Mutation Detection , 2013, Current protocols in bioinformatics.

[42]  M. J. van de Vijver,et al.  Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  Jack Cuzick,et al.  Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. , 2013, The Lancet. Oncology.

[44]  Li Ding,et al.  Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. , 2013, Cell reports.

[45]  Elgene Lim,et al.  Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. , 2013, Cancer cell.

[46]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[47]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[48]  E. Winer,et al.  The natural history of hormone receptor-positive breast cancer. , 2012, Oncology.

[49]  E. Theodorsson,et al.  Ovariectomy and 17β-estradiol replacement in rats and mice: a visual demonstration. , 2012, Journal of visualized experiments : JoVE.

[50]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[51]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[52]  Dafydd G. Thomas,et al.  HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. , 2012, Cancer research.

[53]  Wenjun Guo,et al.  Slug and Sox9 Cooperatively Determine the Mammary Stem Cell State , 2012, Cell.

[54]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[55]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[56]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[57]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[58]  T. Guise,et al.  Cancer to bone: a fatal attraction , 2011, Nature Reviews Cancer.

[59]  Yibin Kang,et al.  Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. , 2011, Cancer cell.

[60]  E. Lander,et al.  Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling , 2010, Proceedings of the National Academy of Sciences.

[61]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[63]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[64]  S. Johnston,et al.  New Strategies in Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.

[65]  Aaron R. Quinlan,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2022 .

[66]  M. Ando,et al.  Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer , 2009, British Journal of Cancer.

[67]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[68]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[69]  Kathryn Trinkaus,et al.  PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer , 2009, Breast Cancer Research and Treatment.

[70]  T. Fehm,et al.  ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients , 2008, Breast Cancer Research.

[71]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[72]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.

[73]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[74]  Jing Liang,et al.  Integration of Estrogen and Wnt Signaling Circuits by the Polycomb Group Protein EZH2 in Breast Cancer Cells , 2007, Molecular and Cellular Biology.

[75]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[76]  T. Guise,et al.  Breast Cancer Metastasis to Bone: Mechanisms of Osteolysis and Implications for Therapy , 2005, Journal of Mammary Gland Biology and Neoplasia.

[77]  Gauri Sabnis,et al.  Therapeutic observations in MCF-7 aromatase xenografts. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[78]  W. Gerald,et al.  Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. , 2005, The Journal of clinical investigation.

[79]  Christian von Mering,et al.  STRING: known and predicted protein–protein associations, integrated and transferred across organisms , 2004, Nucleic Acids Res..

[80]  Jonathan D. Smith,et al.  Safe and effective method for chronic 17beta-estradiol administration to mice. , 2003, Contemporary topics in laboratory animal science.

[81]  Jeffrey W Pollard,et al.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.

[82]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[83]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[84]  F. Kittrell,et al.  Biological and genetic properties of the p53 null preneoplastic mammary epithelium , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[85]  R. Coleman.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.

[86]  T. Yoneda,et al.  Factors regulating the growth of metastatic cancer in bone. , 1999, Endocrine-related cancer.

[87]  B. O’Malley,et al.  Proteasome-dependent degradation of the human estrogen receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[88]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[89]  C. Welsch,et al.  Estrogen induced growth of human breast cancer cells (MCF-7) in athymic nude mice is enhanced by secretions from a transplantable pituitary tumor. , 1981, Cancer letters.

[90]  Rory Stark,et al.  DiBind : Dierential binding analysis of ChIP-Seq peak data , 2016 .

[91]  R. Stark,et al.  DiffBind : Differential binding analysis of ChIP-Seq peak data , 2012 .

[92]  S. Sleijfer,et al.  Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer , 2010, Breast Cancer Research and Treatment.

[93]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..